These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Effects of ketamine on canine cardiovascular function. Diaz FA; Bianco JA; Bello A; Beer N; Velarde H; Izquierdo JP; Jaen R Br J Anaesth; 1976 Oct; 48(10):941-6. PubMed ID: 990147 [TBL] [Abstract][Full Text] [Related]
48. [General pharmacological actions of traxanox sodium. II. Effects on the cardiovascular system]. Nakamura T; Miura Y; Aihara K; Satoh H; Goto K; Tsumagari T Nihon Yakurigaku Zasshi; 1983 Jul; 82(1):79-92. PubMed ID: 6137441 [TBL] [Abstract][Full Text] [Related]
49. Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Lamore SD; Kamendi HW; Scott CW; Dragan YP; Peters MF Toxicol Sci; 2013 Oct; 135(2):402-13. PubMed ID: 23897988 [TBL] [Abstract][Full Text] [Related]
50. Hemodynamic effects of verapamil in the beta-blocked dog. Iberti TJ; Weiner B; Stein JS; Premus G; Benjamin E Crit Care Med; 1985 Feb; 13(2):105-8. PubMed ID: 3967499 [TBL] [Abstract][Full Text] [Related]
51. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog. Greenberg S; Touhey B J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912 [TBL] [Abstract][Full Text] [Related]
52. Cardiac and hemodynamic profile of the new cardiotonic agent, DPI 201-106, in the conscious dog. Gerard JL; Berdeaux A; Giudicelli JF Eur J Pharmacol; 1989 Jun; 165(1):39-49. PubMed ID: 2767134 [TBL] [Abstract][Full Text] [Related]
53. Cardiovascular effects of intravenous pentazocine and cyclazocine in conscious, curarized-conscious, and anesthetized dogs. Küçukhüseyin C J Basic Clin Physiol Pharmacol; 2003; 14(3):235-55. PubMed ID: 14964736 [TBL] [Abstract][Full Text] [Related]
55. [Influence of an antispastic, analgesic combination on blood pressure, dynamics and contractility of the left ventricle in the dog]. Komarek J Arzneimittelforschung; 1976; 26(8):1583-8. PubMed ID: 1036957 [TBL] [Abstract][Full Text] [Related]
57. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of cardiac function in unrestrained dogs and monkeys using left ventricular dP/dt. Buchanan LV; Warner WA; Arthur SR; Gleason CR; Lewen G; Levesque PC; Gill MW J Pharmacol Toxicol Methods; 2016; 80():51-8. PubMed ID: 27063376 [TBL] [Abstract][Full Text] [Related]
59. Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies. Sarazan RD; Kroehle JP; Main BW J Pharmacol Toxicol Methods; 2012 Sep; 66(2):71-8. PubMed ID: 22659561 [TBL] [Abstract][Full Text] [Related]
60. Reversal of volatile anesthetic-induced depression of myocardial contractility by extracellular calcium also enhances left ventricular diastolic function. Pagel PS; Kampine JP; Schmeling WT; Warltier DC Anesthesiology; 1993 Jan; 78(1):141-54. PubMed ID: 8424547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]